Navigation Links
Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
Date:5/3/2012

EAST BRUNSWICK, N.J., May 3, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the Company will present at the Bank of America Merrill Lynch 2012 Health Care Conference on Thursday, May 17, 2012, at 11:20 a.m. PT.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com. Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

SVNT – GContact:Mary Coleman

Carney Noensie Savient Pharmaceuticals, Inc.

Burns McClellan  information@savient.com

cnoensie@burnsmc.com (732) 418-9300

(212) 213-0006 


'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Savient Pharmaceuticals to Present at the Imperial Capital Healthcare Investor Forum
3. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results
4. Savient Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
5. Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
6. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
7. Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
8. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
9. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
10. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
11. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... 2016 , , , WHEN: ... 2016 , , , , LOCATION: , , , Online, ... , , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global ... Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager ... pharmaceutical industry is witnessing an exceptional era. Several new demand spaces, ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
Breaking Medicine News(10 mins):